Zanzalintinib clinical trials
Also written XL092.
How each study uses zanzalintinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zanzalintinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2026 (24); 2 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 14 |
| 2026 | 24 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 33
Exelixis (13) · M.D. Anderson Cancer Center (5) · Washington University School of Medicine (4) · Merck Sharp & Dohme LLC (3) · UNC Lineberger Comprehensive Cancer Center (2) · Stuthi Perimbeti (1) · University of Texas Southwestern Medical Center (1) · Pedro Barata, MD, MSc (1)
Often tested with
Tested in the same studies.
Cabozantinib (1) · Tegavivint (1) · Cemiplimab (1) · C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 (1) · Cobimetinib (1) · Cibisatamab (1) · Docetaxel (1) · Ciforadenant (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test zanzalintinib, phase 3 first.
- Dec 2026Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaPhase 3 · Exelixis
- Dec 2026XL092 in Patients With Metastatic Castration-Resistant Prostate CancerPhase 2 · University of Utah
- Dec 2026Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)Phase 2 · Anwaar Saeed
- Jan 2027Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPhase 1 · Exelixis
- Jun 2027Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCPhase 1 · University of Chicago
- Aug 2027Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaPhase 2 · OHSU Knight Cancer Institute
Studies
Open first, then newest update. How each study uses zanzalintinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingPhase 2Anwaar SaeedNCT06698250Written as Zanzalintinib
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07489495Written as Zanzalintinib
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07227402Written as Zanzalintinib
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingPhase 3ExelixisNCT07750158Written as Zanzalintinib
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2ExelixisNCT07845786Written as Zanzalintinib
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory NeuroblastomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT07527169Written as Zanzalintinib
- Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryRecruitingPhase 2M.D. Anderson Cancer CenterNCT06959511Written as Zanzalintinib
- Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate CancerNot yet recruitingPhase 2Stuthi PerimbetiNCT07623460Written as Zanzalintinib
- Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT07283731Written as Zanzalintinib
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingPhase 2/3ExelixisNCT06943755Written as Zanzalintinib
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Written as Zanzalintinib
- A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaRecruitingPhase 2ExelixisNCT07428616Written as Zanzalintinib
- Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07049926Written as Zanzalintinib
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerRecruitingPhase 1/2Devalingam MahalingamNCT07042919Written as Zanzalintinib
- Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingPhase 1/2University of Texas Southwestern Medical CenterNCT07878689Written as Zanzalintinib
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07470489Written as Zanzalintinib
- Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)RecruitingPhase 2Washington University School of MedicineNCT06926634Written as Zanzalintinib
- XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue SarcomaRecruitingPhase 2Northwestern UniversityNCT06571734Written as Zanzalintinib
- Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingPhase 1Washington University School of MedicineNCT06795009Written as Zanzalintinib
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT06902376Written as XL092
See all 50 studies that test zanzalintinib →
Given beside what is tested · 1 — zanzalintinib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
Stopped1
- Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior TherapyWithdrawnNov 9, 2026NCT07185945
Codes
What other systems call zanzalintinib · ClinicalTrials.gg INT017046
- UNII (FDA) KC2JC2ZA04ZANZALINTINIBConfirmed FDA, Wikidata
- Wikidata Q124353001zanzalintinibConfirmed FDA, Wikidata
- NCI Thesaurus C161598ZanzalintinibOne source FDA
- DrugBank DB17525One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KC2JC2ZA04 | ZANZALINTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q124353001 | zanzalintinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C161598 | Zanzalintinib | One source FDA |
| DrugBank | DB17525 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.